How your DNA affects your response to GLP1 weight loss drugs

Summary

GLP1 receptor agonists are a popular class of medications used to treat obesity, but they do not work exactly the same way for everyone. Recently, scientists discovered that a specific genetic difference might help explain why some people shed more weight or feel sicker than others while taking these drugs. By analyzing data from 23andMe customers, researchers found a variation in the gene responsible for the GLP1 receptor, the cellular landing pad that these medications target.

People carrying this specific genetic variant showed a measurable difference in their treatment results. The research linked this variation to a weight change of 0.76 kilograms, or roughly 1.7 pounds, per inherited copy of the gene. Interestingly, this exact same genetic hotspot is also connected to the likelihood of experiencing common side effects from the medication, such as nausea and vomiting. While the exact biological mechanism remains a mystery, scientists suspect this genetic change might alter how stable the receptor protein is on the surface of a cell.

It is important to view these early findings with caution. The research relied heavily on self-reported survey answers from 23andMe users regarding their body mass index and side effects, which can sometimes be less precise than clinical measurements. Furthermore, when researchers built a model to predict how much weight a patient would lose, they found that lifestyle, environment, and other non-genetic factors actually play a significantly larger role in weight loss than genetics alone.

Why it matters.

As millions of people turn to GLP1 medications to manage obesity, understanding who will benefit most and who might suffer from severe nausea is incredibly valuable. If healthcare providers can eventually use genetic markers to anticipate a patient's response before writing a prescription, they could better tailor treatments to maximize weight loss and minimize discomfort. This discovery represents a promising step toward personalized medicine for obesity.

However, this study also provides a helpful reality check. Because non-genetic elements still dominate how well these drugs work, doctors will continue to emphasize overall lifestyle and clinical history rather than relying solely on genetic screening. Still, the findings pave the way for a deeper understanding of how our bodies interact with these powerful medications, which could eventually help researchers design even more effective and tolerable drugs.

From the source

The story in numbers.

Change in weight loss per allele: 0.76 kg
Missense variant identified in the GLP1 receptor gene: 1

Keep the context

Follow the evidence.

This AI-assisted summary is a starting point. Read the original reporting for its methods, scope, and limitations.

Swapping RNA for DNA gives CRISPR a powerful new target

The gene-editing tool known as CRISPR has revolutionized biology, traditionally relying on a molecule called guide RNA to direct molecular scissors to a specific piece of DNA. However, researchers have discovered a surprising twist. A specific type of molecular scissors known as a Cas12 nuclease can actually be driven by a different genetic navigator. Instead of using traditional guide RNA, this enzyme can utilize guide DNA. This simple substitution fundamentally changes how the tool behaves in a cell. When scientists swap the guide RNA for guide DNA, the Cas12 nuclease stops targeting DNA and instead switches its focus to targeting RNA. RNA is the genetic messenger that helps carry instructions from our genes to the rest of the cell. By just changing the steering mechanism, scientists can completely redirect the cutting machinery to a brand new molecular target. While this discovery significantly expands the overall versatility of the CRISPR toolkit, it is still very preliminary. The current reports are based on an early-stage perspective and lack the quantitative data, clinical validation, and sample size metrics needed to fully understand how well it works in complex organisms.

Nature Biotechnology1 min read

Blood Immune Cells May Drive Spinal Cord Damage in ALS

Amyotrophic lateral sclerosis (ALS) is a severe condition that causes a progressive loss of nerve cells in the brain and spinal cord. While scientists have spent decades studying why these neurons fail, recent research published in Nature Neuroscience points to an unexpected culprit. The study reveals that the immune system is not merely reacting to the disease, but actually acts as an active driver of ALS pathology. To uncover this, researchers used advanced techniques called single-cell and spatial transcriptomic profiling. These tools allow scientists to look at the genetic activity of individual cells and map their exact physical locations in the body. Using these methods, the team observed that immune cells from the bloodstream are infiltrating the central nervous system. Once there, these immune cells undergo a reprogramming process that directly links changes in the blood to the severe spinal cord damage seen in ALS patients.

Nature Neuroscience1 min read

A Domino Effect: How the Immune System Accelerates ALS

Amyotrophic lateral sclerosis, commonly known as ALS, is a devastating disease that gradually destroys the nerve cells responsible for movement. For years, scientists have puzzled over why the condition progresses rapidly in some patients while others survive much longer. Now, researchers at Northwestern University have uncovered a domino-like cascade that helps explain how the disease unfolds. Rather than a single catastrophic event, ALS appears to start with an internal breakdown inside motor neurons involving a toxic buildup of a protein called TDP-43. This initial damage then triggers a secondary, highly destructive response from the body's own immune system. By examining blood and spinal cord samples from hundreds of living and deceased patients, the scientists mapped out exactly where and how this immune reaction occurs. They discovered that inflamed immune cells from the bloodstream travel into the central nervous system, gathering directly at the sites where motor neurons are dying and toxic proteins are accumulating. Patients with the fastest disease progression had the most intense spinal cord inflammation and higher activity in complement genes, which produce proteins that act as the body's first line of immune defense against damage. Interestingly, the study also revealed that this immune response looks different depending on the root cause of the patient's condition. By analyzing the genetic instructions inside individual cells, the researchers found distinct immune patterns when comparing genetic and non-genetic forms of ALS. This suggests that the immune system reacts uniquely to different variations of the disease.

GEN2 min read

Follow your curiosity.

How your DNA affects your response to GLP1 weight loss drugs

Summary

Why it matters.

The story in numbers.

Follow the evidence.

Your next discovery.

Swapping RNA for DNA gives CRISPR a powerful new target

Blood Immune Cells May Drive Spinal Cord Damage in ALS

A Domino Effect: How the Immune System Accelerates ALS

Summary

Why it matters.

The story in numbers.

Follow the evidence.

Your next discovery.

Swapping RNA for DNA gives CRISPR a powerful new target

Blood Immune Cells May Drive Spinal Cord Damage in ALS

A Domino Effect: How the Immune System Accelerates ALS

A little science goes a long way.